Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 65.00 65.20 65.60 65.60 64.00 64.00 5,992,801 16:35:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 65.3 15.4 2.5 26.5 296

Ekf Diagnostics Share Discussion Threads

Showing 3226 to 3248 of 3475 messages
Chat Pages: 139  138  137  136  135  134  133  132  131  130  129  128  Older
DateSubjectAuthorDiscuss
26/3/2021
16:39
I note that EKF gets some good coverage in Moneyweek this week - Scientific-instrument companies are a global success – here's how to play them Companies delivering scientific instruments – products to measure and analyse our world – are crucial to sectors ranging from telecommunications to pharmaceuticals. Dr Mike Tubbs picks his favourite stocks in the sector. by: Dr Mike Tubbs 26 MAR 2021 Full story (part story if not a subscriber) - hTTps://moneyweek.com/investments/stocks-and-shares/share-tips/602992/scientific-instrument-companies-are-a-global Also mentioned in the IC re favourite investment in ESG Fund
wan
24/3/2021
16:47
Polar Technology Trust were one of the 5 presenters on AJ Bell's ISA suggestion webcast yesterday. OPM Ben Rogoff cited telemedicine as one area of great interest and one of their key bottom down themes. He mentioned Teladoc TDOC (probably best known, m cap $30bn) Amwell AMWL(MC $4.5bn)and Babylon, a UK-based company reportedly seeking a listing, possibly in the US. Anyway, this is just further evidence that PMs are very interested in telemedicine which is obviously growing very rapidly but as usual there will be winners and losers. Although slghtly different a glance at the Cambridge Cognition figures this week suggested they are beginning to gain traction. Rogoff cited one estimate that the US alone could save $300bn pa in health costs through effective digitalisation/telemedicine. I know Trellus is very early stage and specialised but it does seem to be an area with excellent prospects if the execution is effective.
srichardson8
24/3/2021
07:49
Staying with long term, tremendous investment opportunities. EKF may be holding serval keys that enable entry to digital front doors - Katie Adams - Friday, February 26th, 2021 Below, seven executives from hospitals and health systems across the country discuss the importance of their organization's digital front door and what strategies went into the building of their websites. A hospital's digital front door is an essential part of its strategy to engage patients throughout each point of their healthcare journey using technology they have already integrated into their everyday lives. Full story - hTTps://www.beckershospitalreview.com/digital-marketing/why-hospitals-need-strong-digital-front-doors-7-execs-weigh-in.html
wan
23/3/2021
18:31
And what a surprise it wasn't that he was wan.
faz
23/3/2021
15:18
To be clear, Chris Mills has been the Non-Executive Chairman of EKF since April 2016. Also to be clear, as per my post above, he was not appointed a director of Trellus Health until yesterday.
wan
23/3/2021
14:54
Yes Buster so that if you wanted you could find out something about the Chairman of EKF and now director of trellis. What;s he been doing since November?
faz
23/3/2021
12:47
From 17th November 2020
busterdog2
23/3/2021
10:04
What a surprise - Chris Mills, https://www.voxmarkets.co.uk/articles/christopher-mills-the-uk-s-best-performing-small-cap-fund-manager-on-the-stocks-he-likes-a063393/
faz
23/3/2021
09:24
Briefly, I note that recently two new directors have been appointed in Trellus Health. Chris Mills (of Harwood capital) was appointed a director in Trellus Health yesterday. And a few days earlier Daniel Mahony (Co-head of Healthcare Polar Capital Global Healthcare Trust)
wan
22/3/2021
16:30
No brainer?
busterdog2
20/3/2021
09:32
I think you may have meant EKF under-promise and over-deliver, time will tell, but lets not try and second guess too much at this stage!
wan
20/3/2021
08:59
Totally agree Wan EKF do like to over deliver Renalytix and Vericci are worth a chunk of money too. I'm more intrigued as to the performance of the underlying business which appears to be strong. AIMHO GLA BTG
btgman
20/3/2021
08:28
It's hard to decipher much from daily share price movements..........until you can look backwards and see whether it was the start of a trend (hindsight)! Hence, I don't get hung up on analysing daily share price movements to support my investment rationale, but everyone to their own though. I am far more interested in the following excerpt from the recent RNS on the 10th March - "The Company's net cash at 31 December 2020 was in excess of GBP21m (as announced in the trading update of 12 January 2021). The Company therefore remains very well capitalised to execute its plans and continues to generate strong operating and net cashflows. As previously announced, the Company expects to pay a dividend again in December 2021 and expects to implement a progressive dividend policy." So, and as I mentioned previously, as of the 10th March, EKF "continues" to generate strong operating and net cashflows. And I thus look forward to the Results Presentation a week next Tuesday, with an early indication that the first quarter of the new financial year has started very well.
wan
20/3/2021
07:53
First sensible thing i hear on this board for ages. Well done for having a stop in place. Managing risk is the only factor under your control with Mr Market being in charge of returns. And yes I agree - as of now, the picture is still very hazy indeed (hence I am flat).
tongosti
19/3/2021
22:14
Yeah but that's "if" that happens. I have a stop in the market and other than that everything else including opinions here are irrelevant
davr0s
19/3/2021
18:57
Considering Mr Market is not making you happy, I am inclined to make you so - whatever you say chap ...Hope this helps?
tongosti
19/3/2021
15:09
Because I have been a skeptic from the very top down? Really impressed with your level of understanding pal. Can anybody please remind me what's the value you lot place on Trellus? Lol. Good weekend girls (and boys!)
tongosti
19/3/2021
14:58
You're such a troll
jsredbird
19/3/2021
13:12
You definitely will if this break down from 60. Point no one is keen to discuss on here as how come the top took place on the day the Pfizer vaccine was announced. Ah well - that's what makes a market ain't it. Lol. PS. For the record - I am not short but always open to all contingencies as this is an odds game. Agnostic to my next trade's direction.
tongosti
19/3/2021
13:07
A lot of it is the wide spread. Can't get too excited about today's move personally
davr0s
19/3/2021
11:29
Haha - I thought no one cares about share price moves? lol. PS. wan - look forward to your next article.
tongosti
19/3/2021
09:17
Why the sudden drop? Pre-Results MM tree shake?
cravencottage
18/3/2021
09:03
Not all tests are created equal! FDA Releases Templates for SARS-CoV-2 Antibody Test Development Mar 17, 2021 NEW YORK – Following on the heels of a template released on Tuesday for developers of tests for serial testing for COVID-19, the US Food and Drug Administration on Wednesday released two templates covering the development of serology tests for antibodies against SARS-CoV-2. One new template is for developers of tests that detect or correlate to neutralizing antibodies against the coronavirus, while another template has been updated to include recommendations for monitoring and evaluating the impact of new SARS-CoV-2 mutations and variants. On FDA's weekly town hall conference call on Wednesday with COVID-19 test developers, Tim Stenzel director of the FDA's Office of In Vitro Diagnostics and Radiological Health, addressed questions about the use of serology tests to assess the immune status of an individual who has received a vaccine for the disease. As more Americans become vaccinated, antibody tests have been discussed as a tool to evaluate whether a vaccine has conferred COVID-19 immunity to an individual. Stenzel said that may not be a good idea presently. Some clinicians have ordered a serology test for patients who had been vaccinated, he said, "and some of those test results are coming back negative, unexpectedly, and there is some concern. "When investigations have been done, it turns out that that vaccine generates an antibody to a spike protein, but the serology test is directed toward the N protein. So, that serology test is obviously not going to be the ideal candidate for clinicians to order an off-label test to take a look at a response to vaccine," Stenzel said. Full story - hTTps://www.360dx.com/regulatory-news-fda-approvals/fda-releases-templates-sars-cov-2-antibody-test-development#.YFLtnq_7SF4 Recall that the Kantaro COVID-SeroKlir already has FDA Emergency Use Authorization (EUA) (in November 2020) having previously received a CE mark in October 2020. And that it targets the spike protein referred to by the FDA yesterday, and that that commentary apparently appears to render some tests of no use....but not the EKF/Kantaro test that indeed targets the spike protein - The Kantaro COVID-SeroKlir kit is a direct ELISA for the quantitative detection of human IgG antibodies to the SARS-CoV-2 virus in serum and plasma (K2-EDTA/Li-Heparin) samples. COVID-SeroKlir has FDA Emergency Use Authorization (EUA) in November 2020 having previously received a CE mark in October 2020. COVID-SeroKlir has demonstrated 97.8% sensitivity and 99.6% specificity for detecting SARS-CoV-2 specific IgG antibodies against two virus antigens, the full-length spike protein and its receptor-binding domain. COVID-SeroKlir is a two-step enzyme-linked immunosorbent assay (ELISA) and can be used by any certified laboratory* without the need for proprietary equipment. Precise and reliable measurement of COVID-19 IgG antibodies hTTps://www.ekfdiagnostics.com/COVID-SeroKlir.html
wan
Chat Pages: 139  138  137  136  135  134  133  132  131  130  129  128  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210516 13:24:34